TGA Evaluates COVID-19 Infant Vaccine

Australian regulators are investigating whether a low dose of Moderna’s COVID-19 vaccine can be given to children aged six months to five years.

A COVID-19 vaccine for infants and young children is one step closer after Australian regulators confirmed they are evaluating a low dose of Moderna’s Spikevax.

There are currently no approved COVID-19 vaccines for children under the age of four, and children ages five and older received the Pfizer shot.

Spikevax is available for children over the age of six and Moderna Australia has applied to the Therapeutic Goods Administration to extend it to younger children.

The TGA confirmed on Friday that it is evaluating using a low dose of Spikevax, 25 micrograms in 0.25 ml, for children between six months and five years.

That’s down from the 50 micrograms in a 0.25-mL measure currently used for children ages six to 11.

Spikevax, an mRNA vaccine, uses a genetic code to enable the production of the coronavirus spike protein.

Immune cells then recognize the spike protein as foreign and begin to mount an immune response against it.

Leave a Comment